IN2014DN03049A - - Google Patents

Info

Publication number
IN2014DN03049A
IN2014DN03049A IN3049DEN2014A IN2014DN03049A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A IN 3049DEN2014 A IN3049DEN2014 A IN 3049DEN2014A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A
Authority
IN
India
Prior art keywords
extracellular matrix
tissue
interstitial
expression
ecm
Prior art date
Application number
Other languages
English (en)
Inventor
Allison A Eddy
Daryl M Okamura
Original Assignee
Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Res Inst filed Critical Seattle Childrens Res Inst
Publication of IN2014DN03049A publication Critical patent/IN2014DN03049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3049DEN2014 2011-10-26 2011-10-26 IN2014DN03049A (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/057935 WO2013062544A1 (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Publications (1)

Publication Number Publication Date
IN2014DN03049A true IN2014DN03049A (ru) 2015-05-15

Family

ID=48168215

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3049DEN2014 IN2014DN03049A (ru) 2011-10-26 2011-10-26

Country Status (7)

Country Link
US (2) US9468612B2 (ru)
AU (1) AU2011379972B2 (ru)
BR (1) BR112014009789A2 (ru)
CA (1) CA2853484C (ru)
IN (1) IN2014DN03049A (ru)
MX (1) MX2014004994A (ru)
WO (1) WO2013062544A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000202A (es) * 2015-07-02 2018-06-27 Horizon Orphan Llc Analogos de cisteamina resistentes a la ado y sus usos.
MX2018011278A (es) * 2016-03-17 2019-07-08 Thiogenesis Therapeutics Inc Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
EP3579923A4 (en) * 2017-02-07 2020-11-18 Children's Hospital Medical Center TREATMENT OF ASTHMA WITH CYSTEAMIN
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
WO2019094862A1 (en) * 2017-11-10 2019-05-16 Wisconsin Alumni Research Foundation Compositions and methods for the inhibition of fibrosis
US20220110894A1 (en) * 2020-10-13 2022-04-14 Accubit LLC - Biotechnology Methods of Treating IgA Nephropathy with Thiol-Containing Molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP2887325B2 (ja) 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション デコリンによる細胞増殖の抑制
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE154514T1 (de) 1989-09-29 1997-07-15 Jolla Cancer Res Found Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix
CA2068204C (en) 1989-11-22 2002-02-12 Arthur Levinson Latency associated peptides and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
ATE233568T1 (de) 1991-11-14 2003-03-15 Jolla Cancer Res Found Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
DE69332026T2 (de) 1992-10-29 2002-10-31 Celtrix Pharma Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
AU5541094A (en) 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
DE69432375T2 (de) 1993-04-30 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
WO1995010610A1 (en) 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
AU2404695A (en) 1994-05-04 1995-11-29 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997040848A1 (en) 1996-04-30 1997-11-06 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
ES2253788T3 (es) 1996-10-25 2006-06-01 Ethicon, Inc. Ensayo de agente anti-fibrotico.
EP0975771B1 (en) 1997-04-18 2007-07-11 Biogen Idec MA Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040087623A1 (en) 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
SI1397364T1 (sl) 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2003097639A1 (en) 2002-05-15 2003-11-27 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
EP1511738A4 (en) 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
EP1575506A4 (en) 2002-07-25 2008-04-23 Scios Inc METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
CA2498460A1 (en) 2002-09-10 2004-03-25 Scios Inc. Inhibitors of tfg.beta.
US7365066B2 (en) 2002-09-17 2008-04-29 Eli Lilly And Company Pyrazolopyridine derivatives as pharmaceutical agents
AU2003268155A1 (en) 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
WO2004048930A2 (en) 2002-11-22 2004-06-10 Scios, Inc. METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
WO2004048381A2 (en) 2002-11-22 2004-06-10 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
US7405299B2 (en) 2002-11-27 2008-07-29 Eli Lilly And Company Compounds as pharmaceutical agents
EP1589960A4 (en) 2002-12-19 2008-09-10 Scios Inc TREATMENT OF OBESITY AND RELATED MANIFESTATIONS USING TGF-BETA INHIBITORS
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7223766B2 (en) 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
RU2006122519A (ru) 2003-12-24 2008-01-27 Сайос, Инк. (Us) Лечение злокачественных глиом ингибиторами тфр-бэта
WO2005092894A1 (en) 2004-03-01 2005-10-06 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
EP1786803A1 (en) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
AU2005280168A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as TGF-beta inhibitors
EP1812450A2 (en) 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
PL3520815T3 (pl) 2005-02-08 2022-04-11 Genzyme Corporation Przeciwciała przeciwko TGFBETA
PT2535044T (pt) 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
AU2007328206B2 (en) * 2006-12-04 2013-08-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
EP2636404B1 (en) 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products

Also Published As

Publication number Publication date
US20170165207A1 (en) 2017-06-15
BR112014009789A2 (pt) 2017-04-25
US9925154B2 (en) 2018-03-27
CA2853484C (en) 2018-08-21
MX2014004994A (es) 2014-08-27
CA2853484A1 (en) 2013-05-02
AU2011379972B2 (en) 2016-05-12
US9468612B2 (en) 2016-10-18
US20140275279A1 (en) 2014-09-18
WO2013062544A1 (en) 2013-05-02
AU2011379972A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
IN2014DN03049A (ru)
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
IL226127A0 (en) A compound containing hydrolyzed proteins and an oligosaccharide for the treatment of skin diseases
MX353955B (es) Hebras de acido hialuronico reticulado y metodos de uso de las mismas.
WO2013040078A3 (en) Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same
EP2648775A4 (en) CONTROL UNIT AND POWER SOURCE FOR IMPLANTABLE BLOOD PUMP
BR112013029800A2 (pt) tratamento de degeneração do disco intervertebral com o uso de células derivadas do tecido do tecido do cordão umbilical humano
MX357749B (es) Tratamiento contra el dolor utilizando células madre placentarias.
CL2013002601A1 (es) Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry.
MX2015015536A (es) Cicatrización de heridas e ingenieria de tejido.
PL3087178T3 (pl) Sposób wytwarzania oksydaz szczawianowych o aktywności optymalnej bliskiej ph fizjologicznemu i zastosowanie takich rekombinowanych oksydaz szczawianowych w leczeniu chorób związanych ze szczawianem
IL215467A0 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
MX2013008530A (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
EP2543396A4 (en) ARTIFICIAL SKIN
EP2894219A4 (en) ARTIFICIAL SKIN FABRIC, ARTIFICIAL SKIN MODEL AND METHOD OF MANUFACTURING THE SAME
EP2785356A4 (en) USE OF PULLULANE TO MITIGATE THE APPEARANCE OF SCARS AND CICATRICIAL TISSUE
ZA201302638B (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
IL215406A0 (en) Electromedical device for the non-invasive reduction or removal of subcutaneous adipose tissue
WO2011038417A9 (en) Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation
EP3768264A4 (en) AROMATIC ALDEHYDE WITH DELAYED AND IMPROVED PHARMACOLOGICAL IN-VITRO AND IN-VIVO ACTIVITY FOR TREATMENT OF SICKLE CELL DISEASE
AU336536S (en) Medical dressing
AU336535S (en) Medical dressing
GB201018154D0 (en) Method of treatment
UA44660U (ru) Способ лечения больных системными заболеваниями соединительной ткани с преимущественным поражением кожи